Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Falbo, Angela ^a   Rocca, Morena ^a   Russo, Tiziana ^a   D'Ettore, Antonietta ^b   Tolino, Achille ^b   Zullo, Fulvio ^a   Orio, Francesco ^c   Palomba, Stefano ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; METFORMIN; MUELLERIAN INHIBITING FACTOR;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIATHERMY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; MYOMECTOMY; OVARY FOLLICLE FLUID; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77955259491     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-16     Document Type: Article

References (32)

1. Anti-Mullerian hormone (AMH): what do we still need to know? A La Marca FJ Broekmans A Volpe BC Fauser NS Macklon ESHRE Special Interest Group for Reproductive Endocrinology - AMH Round Table, Hum Reprod 2009 24 2264 2275 10.1093/humrep/dep210 19520713
2. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. C Weenen JS Laven AR Von Bergh M Cranfield NP Groome JA Visser P Kramer BC Fauser AP Themmen, Mol Hum Reprod 2004 10 77 83 10.1093/molehr/gah015 14742691
3. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. IA Van Rooij FJ Broekmans ER te Velde BC Fauser LF Bancsi FH de Jong AP Themmen, Hum Reprod 2002 17 3065 3071 10.1093/humrep/17.12.3065 12456604
4. Polycystic ovary syndrome. DA Ehrmann, N Engl J Med 2005 352 1223 1236 10.1056/NEJMra041536 15788499
5. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Fertil Steril 2004 81 19 25
6. Ultrasound assessment of the polycystic ovary: international consensus definitions. AH Balen JS Laven SL Tan D Dewailly, Hum Reprod Update 2003 9 505 514 10.1093/humupd/dmg044 14714587
7. Follicle dynamics and anovulation in polycystic ovary syndrome. S Franks J Stark K Hardy, Hum Reprod Update 2008 14 367 378 10.1093/humupd/dmn015 18499708 (Pubitemid 351858976)
8. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. JS Laven AG Mulders JA Visser AP Themmen FH De Jong BC Fauser, J Clin Endocrinol Metab 2004 89 318 323 10.1210/jc.2003-030932 14715867
9. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. T Piltonen L Morin-Papunen R Koivunen A Perheentupa A Ruokonen JS Tapanainen, Hum Reprod 2005 20 1820 1826 10.1093/humrep/deh850 15802325
10. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. S Catteau-Jonard P Pigny AC Reyss C Decanter E Poncelet D Dewailly, J Clin Endocrinol Metab 2007 92 4138 4143 10.1210/jc.2007-0868 17698904
11. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. S Catteau-Jonard SP Jamin A Leclerc J Gonzalès D Dewailly N di Clemente, J Clin Endocrinol Metab 2008 93 4456 4461 10.1210/jc.2008-1231 18697861
12. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. MJ Chen WS Yang CL Chen MY Wu YS Yang HN Ho, Hum Reprod 2008 23 952 957 10.1093/humrep/den015 18256110
13. Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. TD Pache FH de Jong WC Hop BC Fauser, Fertil Steril 1993 59 544 549 8458455
14. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. E Carmina F Orio S Palomba RA Longo G Lombardi RA Lobo, Fertil Steril 2005 84 413 419 10.1016/j.fertnstert. 2004.12.061 16084883
15. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? TL Loucks EO Talbott KP McHugh M Keelan SL Berga DS Guzick, Fertil Steril 2000 74 547 552 10.1016/S0015-0282(00) 00695-6 10973653
16. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. RS Legro P Chiu AR Kunselman CM Bentley WC Dodson A Dunaif, J Clin Endocrinol Metab 2005 90 2571 2579 10.1210/jc.2004-0219 15713728 (Pubitemid 40686293)
17. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. AM Fulghesu P Villa V Pavone M Guido R Apa A Caruso A Lanzone A Rossodivita S Mancuso, J Clin Endocrinol Metab 1997 82 644 648 10.1210/jc.82.2.644 9024269
18. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. S Palomba A Falbo F Zullo F Orio, Endocr Rev 2009 30 1 50 10.1210/er.2008-0030 19056992
19. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. S Palomba A Falbo T Russo F Orio A Tolino F Zullo, Hum Reprod 2010 25 1005 1013 10.1093/humrep/dep466 20106839
20. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. A Bayrak H Terbell R Urwitz-Lane E Mor FZ Stanczyk RJ Paulson, Fertil Steril 2007 87 870 875 10.1016/j.fertnstert.2006.08. 096 17224152
21. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. SM Carlsen E Vanky R Fleming, Hum Reprod 2009 24 1732 1738 10.1093/humrep/dep074 19342396
22. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. F Fbregues C Castelo-Branco F Carmona M Guimer R Casamitjana J Balasch, Gynecol Endocrinol 2010
23. Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. S Palomba A Falbo L Battista T Russo R Venturella A Tolino F Orio F Zullo, Am J Obstet Gynecol 2010 202 1 8 10.1016/j.ajog.2009.11.042 20096821
24. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. J Adams DW Polson S Franks, Br Med J 1986 293 355 359 10.1136/bmj.293.6543.355
25. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. JK Zawadzki A Dunaif, Polycystic ovary syndrome Boston: Blackwell, Dunaif A, Givens JR, Haseltine FP, Merriam GR, 1992 337 384
26. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome an Androgen Excess Society guideline. R Azziz E Carmina D Dewailly E Diamanti-Kandarakis HF Escobar-Morreale W Futterweit OE Janssen RS Legro RJ Norman AE Taylor SF Witchel Androgen Excess Society, J Clin Endocrinol Metab 2006 91 4237 4245 10.1210/jc.2006-0178 16940456
27. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? L Pellatt S Rice HD Mason, Reproduction 2010 139 825 833 10.1530/REP-09-0415 20207725
28. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. L Pellatt L Hanna M Brincat R Galea H Brain S Whitehead H Mason, J Clin Endocrinol Metab 2007 92 240 245 10.1210/jc.2006-1582 17062765
29. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. M Das DJ Gillott E Saridogan O Djahanbakhch, Hum Reprod 2008 23 2122 2126 10.1093/humrep/den185 18550512
30. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. P Pigny S Jonard Y Robert D Dewailly, J Clin Endocrinol Metab 2006 91 941 945 10.1210/jc.2005-2076 16368745 (Pubitemid 43357762)
31. Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis. A Falbo F Orio R Venturella E Rania C Materazzo A Tolino F Zullo S Palomba, J Ovarian Res 2009 2 5 10.1186/1757-2215-2-5 19480717
32. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. S Palomba A Falbo T Russo F Orio A Tolino F Zullo, Hum Reprod 2010 25 1005 1013 10.1093/humrep/dep466 20106839